出血性疾患診断市場：診断検査、適応症、最終用途別-2024-2030年の世界予測

出血性疾患診断市場規模は、2023年に6億6,287万米ドルと推定され、2024年には7億1,026万米ドルに達し、CAGR 7.60％で2030年には11億709万米ドルに達すると予測されます。

出血性疾患診断には、異常出血の根本的な原因を特定し評価するために使用されるさまざまな医療検査や処置が含まれます。先天性または後天性のこれらの疾患は、血液を適切に凝固させる能力に影響を及ぼし、軽傷でも出血が長引いたり、重症の場合は明らかな原因なく自然に出血したりします。出血性疾患の診断アプローチには、臨床的評価と臨床検査の組み合わせが含まれます。これらの診断の目的は、特定のタイプの出血性障害を正確に診断し、その重症度を評価し、適切な治療と管理戦略を導くことです。正確な診断は、効果的な治療を実施し、出血性疾患患者の生活の質を向上させるために極めて重要です。世界の出血性疾患の有病率の上昇と、これらの疾患の早期診断の重要性に対する患者の意識の高まりが、出血性疾患診断の必要性を高めています。しかしながら、先進的な診断検査は高価であるため、低所得地域ではその利用が制限される可能性があり、また、農村部や低開発地域では熟練した専門家が不足しているため、これらの診断ソリューションの普及には大きな課題があります。このような課題にもかかわらず、診断精度の向上とコスト削減を目指した現在進行中の研究開発活動は、世界の出血性疾患診断のアクセシビリティ向上と普及に向けた新たな成長の道を提供しています。

診断検査：凝固因子に関連する特定遺伝子の変異や異常を特定する遺伝子検査の重要性が高まる

出血時間は、一次止血を評価するためにデザインされた伝統的な診断検査であり、通常、前腕の下側に小さな切開を加えた後、血管が出血を止めるまでの時間を評価します。この検査は血小板と血管壁との相互作用を反映するが、凝固因子活性を直接測定するものではないです。出血性疾患に関する遺伝子検査では、個人のDNAを分析して、出血性疾患の原因となる遺伝子異常や突然変異を特定します。これらの検査は、血友病AとB、Von Willebrand病、その他のまれな凝固因子欠損症などの遺伝性出血性疾患の診断に特に有用です。遺伝子検査は確定診断を提供し、保因者検査を可能にし、疾患の重症度に関する洞察を提供し、治療決定の指針となります。血小板凝集能検査は、血液凝固に重要な血球の一種である血小板がどの程度凝集して血栓を形成するかを評価するための一連の検査です。これらの検査は、ADP、コラーゲン、リストセチン、エピネフリンなどの様々な凝集剤に対する血小板の機能を評価します。

適応：異なるタイプのVWDを診断するための出血性疾患診断の重要な用途

血友病Aは古典的血友病とも呼ばれ、血液凝固第VIII因子の欠乏によって引き起こされる遺伝病です。この疾患は、特に筋肉や関節において、けがや手術後の過剰な出血や自然出血を引き起こします。男性に発症し、X連鎖劣性遺伝します。血友病Bはクリスマス病とも呼ばれ、血液凝固第IX因子の欠乏によって起こる。その臨床症状は血友病Aに類似しているが、頻度は低いです。血小板機能障害は、血小板が効果的に血液凝固に寄与できず、異常出血を引き起こすことを特徴とする疾患群です。これらの疾患は、Glanzmann血小板無力症やBernard-Soulier症候群のような先天性のものと、他の病状や薬剤による後天性のものがあります。症状としては、傷口からの出血過多、あざができやすい、出血時間が長くなるなどがあります。これらの疾患の診断には通常、血小板数検査、血小板機能検査、出血時間検査が行われます。フォン・ヴィレブランド病（VWD）は、血栓形成の主要蛋白であるフォン・ヴィレブランド因子（VWF）の機能障害または欠損によって引き起こされる一般的な遺伝性出血性疾患の一つです。VWDは、VWFの量的または質的欠損に基づいて3つの主要なタイプに分類されます。患者は、自然出血、外傷や外科的処置時の過剰出血、月経時の大量出血を経験することがあります。VVDの診断は複雑であり、患者の出血歴の評価、VWF抗原検査、VWFと第VIII因子の活性を評価する機能検査が含まれます。

地域別洞察

南北アメリカ、特に北米では、出血性疾患診断市場は力強い成長を遂げています。米国は、高度に発達した医療インフラ、研究開発への多額の投資、大手市場参入企業の強い存在感により、この成長に大きく貢献しています。血友病Aと血友病Bの患者数が多く、償還政策が支持されていることが、この地域における出血性疾患診断の必要性をさらに高めています。欧州、中東、アフリカ地域は、経済、医療、規制状況が異なるため、多様な市場実績を示しています。欧州は高い認知度、強固な医療システム、出血性疾患診断への多額の投資により、力強い市場成長を維持しています。しかし、中東・アフリカの成長率は鈍化しているもの、医療インフラの整備や診断へのアクセス改善への取り組みが後押しして徐々に増加しています。特に中東は、医療支出の増加と医療水準の向上への取り組みにより、有望視されています。アジア太平洋は、人口の多さ、医療費の増加、出血性疾患に対する意識の高まりから、出血性疾患診断の急成長市場として浮上しています。同地域の新興国は、医療インフラの拡大、出血性疾患の増加、医療アクセス向上のための政府による取り組みにより、出血性疾患診断ソリューションを急速に採用しています。

FPNVポジショニングマトリックス

FPNVポジショニングマトリックスは出血性疾患診断市場の評価において極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を記載しています。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます。フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、出血性疾患診断市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、このセグメントの競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています。

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を記載しています。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発とイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を記載しています。

本レポートは、以下のような主要な質問に対応しています。

1.出血性疾患診断市場の市場規模と予測は？

2.出血性疾患診断市場の予測期間中に投資を検討すべき製品、セグメント、用途、セグメントは何か？

3.出血性疾患診断市場の技術動向と規制枠組みは？

4.出血性疾患診断市場における主要ベンダーの市場シェアは？

5.出血性疾患診断市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 出血性疾患の罹患率の増加
    • 一般の人々と医療従事者の間で出血性疾患に関する認識と取り組みが高まっている
  • 抑制要因
    • 高度な出血性疾患診断メソッドに関連する高コスト
  • 機会
    • 出血性疾患診断における先端技術の新たな可能性
    • ポイントオブケア出血性疾患検査装置の採用増加
  • 課題
    • さまざまな地域における医療規制の複雑さと動的な性質
• 市場セグメンテーション分析
  • 診断検査：凝固因子に関連する特定の遺伝子の変異や異常を特定するための遺伝子検査の重要性が高まっている
  • 適応症：さまざまなタイプのVWDを診断するための出血性疾患診断の重要な用途
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 出血性疾患診断市場：診断検査別

• イントロダクション
• 出血の時間
• 遺伝子検査
• 血小板凝集検査

第7章 出血性疾患診断市場：適応症別

• イントロダクション
• 血友病Aと血友病B
• 血小板機能障害
• フォン・ヴィレブランド病

第8章 出血性疾患診断市場：最終用途別

• イントロダクション
• 診断検査室
• 病院
• 専門クリニック

第9章 南北アメリカの出血性疾患診断市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の出血性疾患診断市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの出血性疾患診断市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

第13章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. BLEEDING DISORDER DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. BLEEDING DISORDER DIAGNOSTICS MARKET DYNAMICS
• FIGURE 7. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. BLEEDING DISORDER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. BLEEDING DISORDER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BLEEDING DISORDER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLEEDING TIME, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLEEDING TIME, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY PLATELET AGGREGATION TESTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY PLATELET AGGREGATION TESTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA A & HEMOPHILIA B, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA A & HEMOPHILIA B, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY PLATELET FUNCTION DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY PLATELET FUNCTION DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 32. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 33. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 34. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 35. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 36. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 37. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 38. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 39. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 40. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 41. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 42. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 43. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 44. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 45. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 46. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 47. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 48. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 49. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 50. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 51. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 52. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 53. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 54. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 55. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 56. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 57. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 58. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 59. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 60. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 61. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 62. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 63. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 64. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 65. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 66. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 67. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 68. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 69. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 70. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 72. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 74. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 76. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 78. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 79. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 80. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 81. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 82. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 83. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 84. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 85. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 86. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 87. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 88. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 89. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 90. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 91. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 92. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 93. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 94. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 95. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 96. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 97. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 98. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 99. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 100. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 101. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 102. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 103. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 104. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 105. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 106. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 107. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 108. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 109. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 110. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 111. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 112. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 113. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 114. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 115. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 116. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 117. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 118. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 119. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 120. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 121. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 122. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 123. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 124. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 125. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 126. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 128. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 130. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 132. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 133. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 134. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 135. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 136. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 137. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 138. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 139. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 140. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 141. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 142. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 143. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 144. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 145. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 146. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 147. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 148. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 149. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 150. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 159. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 160. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 161. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 162. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 163. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 164. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 165. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 166. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 167. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 168. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 169. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 170. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 171. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 172. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 173. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 174. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 175. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 176. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 177. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 178. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 179. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 180. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 181. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 182. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 183. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 184. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 185. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 186. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 187. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 188. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 189. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 190. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 191. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 192. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 193. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 194. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 195. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 196. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 197. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 198. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 199. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 200. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 201. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 202. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 203. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 204. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 205. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 206. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 207. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 208. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 209. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 210. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 211. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 212. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 213. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 214. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 215. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 216. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 217. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 218. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 219. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 220. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 221. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 222. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 223. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 224. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 225. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 226. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 227. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 228. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 229. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 230. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 231. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 232. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 233. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 234. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 235. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 236. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 238. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 240. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 242. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 244. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 246. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 248. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 249. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 250. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 251. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 252. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 253. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 254. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 255. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 256. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 257. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 258. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 259. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 260. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 261. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 262. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 263. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 264. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 265. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 266. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 267. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 268. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 269. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 270. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 271. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 272. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 278. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
• TABLE 280. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 282. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
• TABLE 284. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
• TABLE 285. BLEEDING DISORDER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 286. BLEEDING DISORDER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

[198 Pages Report] The Bleeding Disorder Diagnostics Market size was estimated at USD 662.87 million in 2023 and expected to reach USD 710.26 million in 2024, at a CAGR 7.60% to reach USD 1,107.09 million by 2030.

Bleeding disorder diagnostics encompass a range of medical tests and procedures used to identify and evaluate the underlying causes of abnormal bleeding. These disorders, which can be either congenital or acquired, affect the blood's ability to coagulate properly, leading to prolonged bleeding even from minor injuries or, in severe cases, spontaneous bleeding without any apparent cause. Diagnostic approaches for bleeding disorders include a combination of clinical assessments and laboratory testing. The goal of these diagnostics is to accurately diagnose the specific type of bleeding disorder, assess its severity, and guide appropriate treatment and management strategies. Accurate diagnosis is crucial for implementing effective treatments and improving the quality of life for individuals with bleeding disorders. The rising prevalence of bleeding disorders worldwide, coupled with a growing awareness among patients about the importance of early diagnosis of these conditions, is bolstering the need for bleeding disorder diagnostics. However, the high cost of advanced diagnostic tests, which may limit their accessibility in low-income regions, and the shortage of skilled professionals in rural and underdeveloped areas pose significant challenges to the widespread adoption of these diagnostic solutions. Despite these challenges, ongoing research and development activities aimed at enhancing diagnostic accuracy and reducing costs offer new growth avenues for improved accessibility and adoption of bleeding disorder diagnostics worldwide.

Diagnostic Tests: Growing importance of genetic testing to identify mutations or abnormalities in specific genes associated with clotting factors

Bleeding time is a traditional diagnostic test designed to evaluate primary hemostasis and assess the duration it takes for blood vessels to cease bleeding after a small incision, typically on the underside of the forearm. It reflects the interaction between platelets and the vascular wall but does not measure clotting factor activity directly. Genetic testing in the context of bleeding disorders involves analyzing an individual's DNA to identify genetic abnormalities or mutations that may lead to a bleeding disorder. These tests are particularly valuable for diagnosing inherited bleeding disorders, including hemophilia A and B, Von Willebrand disease, and other rare clotting factor deficiencies. Genetic tests provide definitive diagnoses, enable carrier testing, offer insights into disease severity, and guide treatment decisions. Platelet aggregation tests are a suite of assays used to evaluate how well platelets, a type of blood cell crucial for clotting, clump together to form a blood clot. These tests assess the function of platelets in response to various aggregating agents such as ADP, collagen, ristocetin, and epinephrine.

Indication: Significant applications of bleeding disorder diagnostics to diagnose different types of VWD

Hemophilia A, also referred to as classical hemophilia, is a genetic disease caused by a deficiency of clotting factor VIII. This condition leads to excessive bleeding following injury or surgery and spontaneous bleeding episodes, notably in muscles and joints. It affects males, being passed on through an X-linked recessive pattern. Hemophilia B, also called Christmas disease, is caused by a deficiency of clotting factor IX. Its clinical manifestations are similar to Hemophilia A, though it is less common. Platelet function disorders are a group of conditions characterized by the inability of platelets to effectively contribute to blood clotting, leading to abnormal bleeding. These disorders can be congenital, such as Glanzmann thrombasthenia or Bernard-Soulier syndrome, or acquired due to other medical conditions or medications. Symptoms include excessive bleeding from wounds, easy bruising, and prolonged bleeding times. Diagnosis of these disorders typically involves platelet count tests, platelet function assays, and bleeding time tests. Von Willebrand Disease (VWD) is one of the common inherited bleeding disorders caused by a dysfunction or deficiency of the von Willebrand factor (VWF), a major protein in blood clot formation. VWD is categorized into three main types based on the quantitative or qualitative defect of VWF. Patients may experience spontaneous bleeding, excessive bleeding during injury or surgical procedures, and heavy menstrual bleeding. Diagnosis of VVD is complex and includes evaluating the patient's bleeding history, VWF antigen tests, and functional assays to assess the activity of VWF and factor VIII.

Regional Insights

In the Americas, particularly in North America, the market for bleeding disorder diagnostics is experiencing robust growth. The United States contributes majorly to this growth with a highly advanced healthcare infrastructure, significant investments in R&D, and a strong presence of major market players. A significant number of hemophilia A & hemophilia B patients and supportive reimbursement policies further fuel the need for bleeding disorder diagnostics in the region. The EMEA region shows a diverse market performance owing to varying economic, healthcare, and regulatory landscapes. Europe maintains a strong market growth with high awareness levels, strong healthcare systems, and significant investments in bleeding disorders diagnostics. However, growth rates in the Middle East and Africa are slower but gradually increasing, driven by efforts to improve healthcare infrastructure and access to diagnostics. The Middle East, in particular, shows promise with rising healthcare expenditure and initiatives to enhance healthcare standards. The APAC region is emerging as a rapidly growing market for bleeding disorder diagnostics, attributed to its large population base, increasing healthcare expenditure, and growing awareness of bleeding disorders. Emerging economies in the region are rapidly adopting bleeding disorder diagnostics solutions owing to their expanding healthcare infrastructure, rise in bleeding disorders, and initiatives by governments to improve healthcare access.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Bleeding Disorder Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Bleeding Disorder Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Bleeding Disorder Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ARUP Laboratories, Baxter International Inc., Bayer AG, Bio-Rad Laboratories, Inc., Cepheid by Danaher Corporation, CSL Limited, F. Hoffmann-La Roche Ltd., HORIBA, Ltd., Hyphen BioMed by Sysmex Corporation, Laboratory Corporation of America Holdings, Novo Nordisk A/S, Precision BioLogic, rHEALTH, Siemens AG, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Bleeding Disorder Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Diagnostic Tests
  • Bleeding Time
  • Genetic Tests
  • Platelet Aggregation Tests

• Indication
  • Hemophilia A & Hemophilia B
  • Platelet Function Disorders
  • Von Willebrand Disease

• End-use
  • Diagnostic Laboratories
  • Hospitals
  • Specialized Clinics

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Bleeding Disorder Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Bleeding Disorder Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Bleeding Disorder Diagnostics Market?

4. What is the market share of the leading vendors in the Bleeding Disorder Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Bleeding Disorder Diagnostics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of bleeding disorders
    • 5.1.1.2. Growing awareness and initiatives about bleeding disorders among the general population and healthcare professionals
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with advanced bleeding disorder diagnostics methods
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging potential of advanced technologies in bleeding disorder diagnostics
    • 5.1.3.2. Growing adoption of point-of-care bleeding disorder testing devices
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory complexities and the dynamic nature of healthcare regulations across different regions
• 5.2. Market Segmentation Analysis
  • 5.2.1. Diagnostic Tests: Growing importance of genetic testing to identify mutations or abnormalities in specific genes associated with clotting factors
  • 5.2.2. Indication: Significant applications of bleeding disorder diagnostics to diagnose different types of VWD
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Bleeding Disorder Diagnostics Market, by Diagnostic Tests

• 6.1. Introduction
• 6.2. Bleeding Time
• 6.3. Genetic Tests
• 6.4. Platelet Aggregation Tests

7. Bleeding Disorder Diagnostics Market, by Indication

• 7.1. Introduction
• 7.2. Hemophilia A & Hemophilia B
• 7.3. Platelet Function Disorders
• 7.4. Von Willebrand Disease

8. Bleeding Disorder Diagnostics Market, by End-use

• 8.1. Introduction
• 8.2. Diagnostic Laboratories
• 8.3. Hospitals
• 8.4. Specialized Clinics

9. Americas Bleeding Disorder Diagnostics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Bleeding Disorder Diagnostics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Bleeding Disorder Diagnostics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. ARUP Laboratories Makes History with Diagnostic Test for Hemophilia A
  • 12.3.2. FDA Approves First Gene Therapy for Adults with Severe Hemophilia A
• 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio